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RATE OF DELINE OF RABBIT ANTI-THYMOCYTE GLOBLULIN (RATG)
SERUM LEVELS IN CHILDREN IS RELATED TO IMMUNE RECONSTITU-
TION AND CHIMERISM STATUS AFTER REDUCED-INTENSITY ALLOGE-
NEIC TRANSPLANTATION
Horn, B.N.1, O’Brien, S.1, Hwang, J.1, Oon, C.Y.1, Cowan, M.J.1
1UCSF, San Francisco, CA.
We measured rabbit antithymocyte globulin levels until 6
months after hematopoietic stem cell transplantation (HSCT)
in 14 children undergoing reduced intensity conditioning (RIC)
and HSCT and in 4 patients receiving haploidentical T-cell
depleted transplants for malignant and non-malignant disor-
ders. Twelve patients received 8mg/kg of rATG, and 6 patients
received 3.5-4.5 mg/kg of rATG. The majority of patients
(72%) underwent unrelated or mismatched transplants. At four
years post transplant, overall survival and event-free survival
were 839% and 7210.6%, respectively; however, the en-
graftment failure rate was high (23%).
Serum active and total rATG levels cleared to subtherapeutic
levels (1 g/ml) by 2 and 16 weeks post transplant, respectively.
CMV reactivation occurred in 54% of patients at risk, and EBV
infection occurred in 22% of patients. Infections were treated
successfully, except in patients with graft failure. Acute and chronic
graft-versus host disease developed in 40% of patients.
Patients who recieved 8 mg/kg of rATG were further divided in
two groups based on the rate of decline of serum total rATG levels.
Five patients were in the group with the slow rate of decline and 6
patients in the group with fast rate of decline of total rATG.
Patients with slow rATG clearance took longer to recover all
lymphocyte subsets and B- and T-cell function; however, statistical
signiﬁcance was reached only for CD8 subset, isohemagglutinin
titer and IgM levels. We also found that the rate of decline of total
rATG level was associated with chimerism status at 1-year post
transplant. Of 4 patients with a fast rATG decline, 3 had full donor
chimerism and 1 mixed donor chimerism at one year post trans-
plant; all 4 patients with a slow decline of rATG were mixed
chimeras at 1-year post transplant (p for Fisher exact0.03). How-
ever, graft loss was not associated with the rate of decline of rATG.
Conclusion: The use of rATG in children results in low inci-
dence of GVHD, but does not decrease the risk of graft rejection.
rATG clearance in children is heterogenous, and the rate of elim-
ination of rATG may play a role in immune reconstitution and
chimerism after reduced intensity transplants. Understanding the
pharmacokinetics and causes of individual variations in the clear-
ance of rATG may lead to more efﬁcacious use of this potent
immunosuppreessive medication.
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UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FOR TRANSFU-
SION-DEPENDENT THALASSEMIA – A RETROSPECTIVE AUDITED ANAL-
YSIS OF 41 CONSECUTIVE PATIENTS
Jaing, T.-H.1, Tan, P.2, Rosenthal, J.3, Chan, L.L.4, Lin, H.-P.5,
Tan, P.-L.6, Nademanee, A.3, Karanes, C.3, Gjertson, D.7, Wang, B.8,
Petz, L.8, Chow, R.8,9,10 1Chang Gung Children’s Hospital & Univer-
sity, Linkou, Taiwan; 2Mount Elizabeth Hospital, Singapore; 3City of
Hope National Medical Center, Duarte, CA; 4University of Malaya
Medical Center, Kuala Lumpur, Malaysia; 5Subang Jaya Medical Cen-
ter, Malaysia; 6National University Hospital, Singapore; 7UCLA School
of Public Health, Los Angeles, CA; 8StemCyte International Cord Blood
Center, Arcadia, CA; 9StemCyte Taiwan National Medical Center,
Linkou, CA; 10StemCyte Research Institute, Arcadia, CA.
UCBT offers a cure for thalassemia and CB has advantages as
a stem cell source for minorities, where thalassemia is prevalent.
Previously mortality risks outweigh beneﬁts and cell dose is
critical for UCBT. With strategies that maximize cell dose -
using non-red cell reduced plasma depleted (PD) CB, no post-
thaw wash (NW), and double cord transplantation (DCT),
promising results may be achieved with UCBT in selected
thalassemics. Between 7/01 and 9/06, 47 UCBT were performed
after myeloablative therapy in 41 pediatric patients with thalas-
semia major (7 DCT & 1 re-transplant) at 14 transplant centers
(TC) using 81% PD CB with 91% NW. Patient status: 19
Pesaro class 1, 4 class 2, 1 class 3, and 17 status unknown. The
median age was 5 yo (range 0.3-20 yo) with a median weight of
18 kg (range 8-45 kg). The data was audited by external agen-
cies. No signiﬁcant adverse events were observed despite major
ABO incompatibility in some cases. Kaplan-Meier estimates of
ANC500, platelet 20K and platelet 50K engraftment rate with
donor chimerism were 866%, 748% and 768%, and me-
dian times to ANC500, platelet 20K and platelet 50K engraft-
ment were 16 days (range 11-32), 38 days (range 16-99) and 57
days (range 30-106) after transplantation respectively. 7 patients
died with 2 deaths prior to day 20 and one traumatic head injury.
32 patients are known to be alive, no survival data for 2 patients,
5 with autologous recovery, and 34 engrafted with a mean and
median follow up time of 440 and 243 days respectively (range
8-1,750 days) as of 9/18/2006. Median day to hospital discharge
was day 64 (range 22-121 days). Experienced TC (5 cases of
UCBT for thalassemia) were compared with less experienced
TC, and CB that were post-thaw washed were compared with
CB that were NW. Results appear to show improvement with
TC experience and NW. The role of plasma depletion vs. RBC
depletion was studied by matching age, weight, TNC dose,
#HLA matches, conditioning regimen, TC experience, and NW
status between the two groups , and results trended towards
improvements in engraftment and DFS for PD CB. To our
knowledge, this is the largest multi-institutional UCBT series
for thalassemia and demonstrate that UCBT may be a promising
approach for the curative therapy of thalassemia major and
engraftment of 936% and 1-year DFS of 888% are attain-
able with experience and judicious patient selection when cell
dose is optimized with PD CBU, no post-thaw wash and DBT
when necessary.
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RELAPSE FOLLOWING BUSULFAN/CYCLOPHOSPHAMIDE CONDITION-
ING IN CHILDREN AND ADOLESCENTS UNDERGOING HLA-IDENTICAL
SIBLING TRANSPLANTATION FOR STABLE PHASE CHRONIC MYELOID
LEUKEMIA
Lehmann, L.E.1,2, Buonanno, M.1,2, Duncan, C.N.1,2 1Dana Farber
Cancer Institute, Boston, MA; 2Children’s Hospital Boston, Boston, MA.
Chronic Myelogenous Leukemia (CML) while primarily a
disease of adults accounts for up to 5% of childhood leukemias.
Allogeneic hematopoietic stem cell transplant (HSCT) remains
the only curative modality and is recommended for children and
adolescents particularly if a matched sibling donor is available.
Cyclophosphamide (CY) and busulfan (Bu) have been shown to
be an effective conditioning regimen for CML in the setting of
a HLA-matched related donor whereas total body irradiation
(TBI) based regimens are usually used if the donor is unrelated.
Bu/CY is an attractive approach,especially in younger patients,
as it has less effect on growth as well as less risk of secondary
malignancies, thyroid dysfunction and cataract formation. From
1995 through 2005 we transplanted 9 children and adolescents
from matched sibling donors in the ﬁrst stable phase of CML.
The median ages of the patients and donors at transplant were
13 (range 1-18) years and 12 (2-21 )years. All patients went to
HSCT within 4 mos of diagnosis. 3 patients (transplanted be-
fore 7/01) received only hydroxyurea (HU) pre-SCT and CY/
TBI for conditioning. These patients have 100% leukemia-free
survival and none have chronic graft versus host disease
(GVHD). The remaining 6 children were conditioned with
Bu/CY , with targeted Bu levels in 5/6. 3 received imatinib
pre-HSCT, 2 received HU alone and one received no CML-
directed therapy. 5 of these 6 children (83%) have relapsed
following HSCT. 1 relapsed into lymphoid blast crisis 11
months post-HSCT; he is now 2 yrs post- unrelated donor
HSCT in molecular remission (MR) with limited chronic
GVHD . 4 of the 6 experienced molecular relapses at a median
time of 20 (range 9-22 ) months post-HSCT. All received donor
lymphocye infusions (DLI) (2 patients received DLI x1, 2 pa-
tients required DLI x3 with increasing T-cell dose) and re-
attained molecular remission within 3 months of the last DLI. 1
has limited fasciitic chronic GVHD , 1 has oral GVHD and 2
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have no GVHD. The remaining patient has not relapsed but has
chronic GVHD of the liver and GI tract. Despite the high rate
of relapse seen in this series all patients are currently in molec-
ular remission with a performance status of 100% and without
extensive CGVHD. Thus Bu/Cy appears to be an effective
approach and avoids TBI-speciﬁc toxicity.However frequent
monitoring of disease status is essential to ensure that relapse is
ascertained in a timely manner and appropriate interventions
are taken.
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NEURODEVELOPMENTAL OUTCOMES OF UNRELATED UMBILICAL
CORD BLOOD TANSPLANTATION FOR METACHROMATIC LEUKODYS-
TROPHY
Martin, H.P.1, Poe, M.D.1, Szabolcs, P.2, Martin, P.2, Suhag, P.2,
Vinod, P.2, Joanne, K.2, Maria, E.L.1 1University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2Duke University Medical Center,
Durham, NC.
Metachromatic leukodystrophy is an autosomal recessive lysoso-
mal storage disorder caused by arylsulfatase A deﬁciency (ARSA).
ARSA prevents the breakdown of cerebroside 3-sulfatate. Sulfati-
des accumulate within lysosomes of myelin forming cells in the
central and peripheral nervous system causing demyelination and
progressive neurologic deterioration that leads to dementia, sei-
zures, blindness, deafness and subsequent death. It has a wide
variability in age of onset and disease severity. We hypothesized
that transplantation of umbilical-cord blood from unrelated donors
would positively alter clinical outcomes in patients affected with
MLD who are minimally symptomatic.
Fourteen patients with Metachromatic Leukodystrophy referred
to Duke University Medical Center, underwent transplantation
with umbilical cord blood from unrelated donors after myeloabla-
tive chemotherapy. Age at transplant ranged from 0.17 to 16.4
years with a median of 5.2 years. Engraftment, survival, neuro-
physiologic measures, and neurodevelopmental function were se-
rially evaluated.
Thirteen of 14 patients engrafted after initial transplant. One
patient underwent a second transplant, with successful engraft-
ment. Eight patients are surviving, 4 died of viral infections, 1 of
respiratory failure and one of EBV lymphoma. BAERS and NCV
became abnormal early in the disease course and continued to
worsen after transplant. EEG and VEP were only abnormal later in
the disease course.
Transplantation of umbilical-cord blood from unrelated donors
was beneﬁcial to asymptomatic children. Mildly symptomatic chil-
dren showed deterioration of motor skills, but maintained cogni-
tive function at pre transplant level. Children with moderate to
severe disease at the time of transplant showed no improvements in
neurodevelopmental function. As in other leukodystrophies, early
intervention is necessary for optimal outcome.
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NEURODEVELOPMENTAL OUTCOMES OF CHILDREN WITH MPS II AF-
TER UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION
Maria, E.L.1, Michele, P.D.1, Vinod, P.2, Joanne, K.2, Paul, S.2 1Uni-
versity of North Carolina at Chapel Hill, Chapel Hill, NC; 2Duke
University, Durham, NC.
MPS II or Hunter’s Syndrome is due to the deﬁciency of the
lysosomal enzyme iduronate sulfatase that results in lysosomal
accumulation of dermatan and heparan sulfate, with progressive
tissue and organ dysfunction, and in the severe form, premature
death. The severe form of MPS II is characterized by mental
retardation, communicating hydrocephalus, hearing impair-
ment, coarse facial features, hepatomegaly, obstructive airway
disease, cardiac dysfunction, joint stiffness and skeletal involve-
ment. They typically die in their mid teens secondary to severe
neurological involvement and/or airway obstruction compli-
cated by cardiac disease. Bone marrow transplantation, tested
more than a decade ago, in a few patients was not felt to be
beneﬁcial. We hypothesized that unrelated umbilical cord blood
transplantation would be beneﬁcial if treatment is offered before
patients have severe CNS disease. Between December 02 and
October 2005, 5 patients with MPS II received unrelated um-
bilical cord blood transplantation at Duke University Medical
Center. The patient’s age at transplant ranged from 0.26 to 3.4
years with a median of 1.4 years. Follow up ranged from 1.7 to
3.7 years with a median of 1.9 years. Four patients engrafted full
donnor and one had mixed donnor chimera. This patient died of
GvHD complications after a second transplant. The 4 survivors
have limitted skin GvHD. The oldest patient required a VP
Shunt because of increased intracraneal pressure. He had sinus-
itis and developed a subdural empyema that required surgical
drainage. All patients have mild hearing loss. The four surviving
patients continue to gain cognitive, language, adaptive and mo-
tor skills with the oldest patient having slower gains.
We conclude that patients with MPS II succesfully treated with
unrelated umbilical cord blood transplantation continue to gain
neurodevelopmental skills in all areas despite mild hearing loss.
Further follow up will be needed to determine if the adequate rate
of skill acquisition will continue.
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VENO-OCCLUSIVE DISEASE IN PEDIATRIC HSCT: THE CHILDREN’S ON-
COLOGY GROUP EXPERIENCE
Nieder, M.L.1, Hale, G.A.2, Wall, D.A.3 1All Children’s Hospital, St.
Petersburg, FL; 2St. Jude Children’s Research Hospital, Memphis, TN;
3Texas Transplant Institute, San Antonio, TX.
Veno-occlusive disease (VOD) of the liver occurs in a minority
of children undergoing HSCT. Historically, the incidence and
severity of this transplant-related complication is lower in the
pediatric population than in their adult counterparts undergoing
myeloablative transplants. Reducing the intensity of the prepar-
ative regimen is associated with less VOD, but this transplant
approach is not commonly used in the pediatric setting. To
determine the incidence and severity of VOD in children, we
surveyed each of the approved transplant centers in the Chil-
dren’s Oncology Group. We received surveys from 38 centers
(45% response). From January 1, 2003 through December 31,
2005, these COG centers performed 2,725 transplants (45% of
COG total). These centers performed an average of 24 trans-
plants per year (range 8-188). Table 1 summarizes our ﬁndings.
The overall incidence of VOD was 10.3% (mild3.1%;
mod5.2%; severe 2%). Of the children with VOD, 18.5%
received Deﬁbrotide (DF) (usually on compassionate basis).
There were 49 children who died from VOD, representing a
mortality rate of 1.8% for the total cohort but 17% for those
who develop signs of VOD. These ﬁndings suggest that VOD is
still a notable complication in the pediatric HSCT setting, with
7.2% of patients overall developing moderate or severe disease.
Since a majority (93%) of pediatric HSCT are myeloablative,
VOD is expected to remain a major cause of transplant related
morbidity and mortality. Thus, it is important to study new
agents and strategies that can reduced this complication in
children.
COG Transplants 2003-2005*
2003 2004 2005 Total
# of Allo 504 510 513 1,527
# of Auto 415 343 440 1,198
# of RIC 73 58 69 200
Unrelated 260 268 259 787
VOD-mild 32 32 20 84
VOD-mod 36 48 57 141
VOD-severe 18 17 21 56
VOD-Death 7 16 26 49
Total VOD 86 97 98 281
*45% of COG Transplant Centers reporting
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